anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants in the research will undergo a three-week online rehabilitation program, three times a week, lasting 40-45 minutes each session. The program includes posture, stretching, joint range of motion, strengthening exercises, pain education, and discussions. Conducted via Zoom, only the practitioner will be present during sessions. Non-attendance for two consecutive sessions or failure to provide feedback will result in exclusion. Exercises cover various body areas and types, including posture correction, range of motion, stretching, isometric neck and shoulder exercises, stick exercises, and strengthening exercises.
BACKGROUND: Rapid recognition of frailty in older patients in the ED is an important first step toward better geriatric care in the ED. We aimed to develop and validate a novel frailty assessment scale at ED triage, the Emergency Department Frailty Scale (ED-FraS).
METHODS: We conducted a prospective cohort study enrolling adult patients aged 65 years or older who visited the ED at an academic medical center. The entire triage process was recorded, and triage data were collected, including the Taiwan Triage and Acuity Scale (TTAS). Five physician raters provided ED-FraS levels after reviewing videos. A modified TTAS (mTTAS) incorporating ED-FraS was also created. The primary outcome was hospital admission following the ED visit, and secondary outcomes included the ED length of stay (EDLOS) and total ED visit charges.
RESULTS: A total of 256 patients were included. Twenty-seven percent of the patients were frail according to the ED-FraS. The majority of ED-FraS was level 2 (57%), while the majority of TTAS was level 3 (81%). There was a weak agreement between the ED-FraS and TTAS (kappa coefficient of 0.02). The hospital admission rate and charge were highest at ED-FraS level 5 (severely frail), whereas the EDLOS was longest at level 4 (moderately frail). The area under the Receiver Operating Characteristic curve (AUROC) in predicting hospital admission for the TTAS, ED-FraS, and mTTAS were 0.57, 0.62, and 0.63, respectively. The ED-FraS explained more variation in EDLOS (R2 = 0.096) compared with the other two methods.
CONCLUSIONS: The ED-Fras tool is a simple and valid screening tool for identifying frail older adults in the ED. It also can complement and enhance ED triage systems. Further research is needed to test its real-time use at ED triage internationally.
Flavonoids, e.g. Gingko biloba extract, form on dissolution in a hydrophilic peptide, e.g. gelatin, stable solid or liquid solutions, which considerably improves the activity or the availability of such substances in pharmaceuticals, cosmetics and dietetic foodstuffs (health care). A pharmaceutical composition which contains rutin in molecular dispersion in a basic substance comprising a hydrophilic peptide with a molecular weight above 100 D, e.g. gelatin, in addition to pharmaceutically customary vehicles and ancillary substances, has in vivo the effect of the Gingko biloba extract. Metabolites of rutin detected in renal excretions are quercetin, kaempferol and isorhamnetin. <IMAGE>
* Do not drive, operate heavy machinery, or participate in any other possibly dangerous activities until you know how you react to this medicine. Oxycodone HCl Controlled-Release Tablets can make you sleepy. 
  * Do not drink alcohol while using Oxycodone HCl Controlled-Release Tablets. It may increase the chance of getting dangerous side effects.
  * Do not take other medicines without your doctor’s approval. Other medicines include prescription and non-prescription medicines, vitamins, and supplements. Be especially careful about products that make you sleepy.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The Study 1 was a multicenter, randomized, double-blind, active-controlled study in neonates who were experiencing seizures [see Clinical Studies (14)]. Patients were infants younger than 14 days of age with gestational ages between 36 and 44 weeks. Overall, 106 neonates (51 female and 55 male) were randomized to receive either phenobarbital (N=42) or levetiracetam (N=64) as their initial treatment. Patients received up to two 15-minute infusions of their initially assigned treatment (loading dose(s)) followed by maintenance treatment of up to 5 days. Mean durations of phenobarbital and levetiracetam treatments were 4.3 and 4 days, respectively. 

Table 2 summarizes the adverse reactions that occurred in 2% or more of neonates in Study 1. Incidences are displayed for neonates who received phenobarbital only and for neonates who received levetiracetam only. Because patients in Study 1 were neonates, adverse reactions that are verbally reported could not be assessed in this study.

Table 2: Adverse Reactions That Occurred in At Least 2% of Neonates Overall in Study 1 by Treatment Received

* Fifty-five neonates received both phenobarbital and levetiracetam and they had a similar adverse reaction profile as neonates who received only phenobarbital.
Patients receive neratinib PO QD on days 1-21 (days 8-21 of cycle 1, then days 1-21 in cycles thereafter for PD study) of each cycle and trastuzumab deruxtecan IV over 30-90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection, CT scan and echocardiograpahy or MUGA scan throughout study. Additionally, patients may undergo a tissue biopsy at baseline.
The coronal pulp tissue was completely removed with a high-speed sterile carbide bur under abundant water coolant. A cotton pellet moistened with 2.5% sodium hypochlorite was used to achieve hemostasis. Following the achievement of hemostasis, an average of 3 mm thick MTA material (Angelus, Londrina, PR, Brazil) was used to cover the pulp chamber. In the same session, the pulp chamber was closed with approximately 2 mm thick flowable glass ionomer cement (Glass Liner, WP), and coronal restoration was completed with composite filling (Estelıte® Sıgma Quıck, Tokuyama).
This study provides an in-depth perspective of moxibustion as a treatment option for urinary incontinence (UI), focusing on its clinical efficacy, underlying mechanisms, and potential integration into standard care practices. Moxibustion, rooted in traditional Chinese medicine, involves the targeted application of heat from burning moxa at specific acupoints. Analyzing data from randomized controlled trials and retrospective studies, the study suggests that moxibustion effectively reduces UI symptoms and improves quality of life with minimal adverse effects. The therapeutic benefits are attributed to enhanced blood circulation, improved neurological functions, and hormonal balance, facilitating tissue repair, and urinary system functionality. Despite encouraging outcomes, existing research exhibits limitations, including small sample sizes, and inconsistent methodologies. Future research should aim to address these gaps by conducting larger, standardized multicenter trials to provide more definitive evidence of moxibustion's effectiveness. Additionally, integrating moxibustion into comprehensive treatment strategies for UI and promoting its inclusion in clinical guidelines could enhance its acceptance and application in modern medical practice. This study underscores the potential of moxibustion as a non-alternative in the management of UI, warranting further exploration and validation in clinical settings.
The invention relates to a colloidal dispersion, characterized in that it comprises a cerium oxide and at least one additive selected amongst .beta. dicetones, the carboxylic monoacides comprising an .alpha. or .beta. hydroxy function and the diols. It also relates to a redispersible composition in the form of a cerium oxide based colloidal dispersion and the same said additives. The colloidal dispersion of the invention may be obtained by a process which is characterized in that at least one above mentioned additive is added to a starting cerium oxide colloidal dispersion. Finally, the invention relates to the use of a dispersion of the above type or of the type obtained by redispersing a redispersible composition, on a substrate as anticorrosion agent, in a cosmetic composition, for catalytic purposes particularly in motor vehicule post combustion, for lubrication or in ceramics.
No specific information on emergency treatment of overdosage in humans is available. Should accidental ocular overdosage occur, flush eye(s) with water or normal saline. The most common effects expected with overdosage of a beta-adrenergic blocking agent are bradycardia, bronchospasm, congestive heart failure and hypotension.

In case of ingestion, treatment with Carteolol Hydrochloride Ophthalmic Solution should be discontinued and gastric lavage considered. The patient should be closely observed and vital signs carefully monitored. The prolonged effects of carteolol must be considered when determining the duration of corrective therapy. On the basis of the pharmacologic profile, the following additional measures should be considered as appropriate:

Symptomatic Sinus Bradycardia or Heart Block: Administer atropine. If there is no response to vagal blockade, administer isoproterenol cautiously.

Bronchospasm: Administer a beta2-stimulating agent such as isoproterenol and/or a theophylline derivative.

Congestive Heart Failure: Administer diuretics and digitalis glycosides as necessary.

Hypotension: Administer vasopressors such as intravenous dopamine, epinephrine or norepinephrine bitartrate.
Ketorolac 0.5 mg/kg, maximum single dose = 30 mg. Administered once by intravenous route.
The present invention relates to methods of identifying whether a candidate compound is a modulator of an orphan G protein-coupled receptor (GPCR). Preferably the GPCR is human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In some embodiments, overexpression of the GPCR promotes survival of cardiomyocytes. In some embodiments, overexpression of the GPCR rescues cardiomyoctes from hypoxia/reoxygenation induced apoptosis. In some embodiments, the GPCR is down-regulated in individuals with congestive heart failure. Agonists of the invention are envisioned to be useful as therapeutic agents for the treatment of ischemic heart disease, including myocardial infarction, post-myocardial infarction remodeling, and congestive heart failure.
Participants will receive intravenous risankizumab dose A at Week 0, 4 ,8 followed by subcutaneous (SC) risankizumab dose B every 8 weeks through Week 48. Participants who complete the Week 48 visit will continue SC risankizumab for up to an additional 220 weeks.
Long-term ADT of 2-3years were administered. Neoadjuvant ADT within 6 months was allowed.Then patients with high-risk prostate cancer recieve stereotactic body radiotherapy with pelvic radiation and GTV boost based on multiparameter magnetic resonance image.
Concentrated Dextrose in Water is administered by slow intravenous infusion (a) after admixture with amino acid solutions or (b) after dilution with other compatible IV fluids. Dosage should be adjusted to meet the requirements of each individual patient.

The maximum rate at which dextrose can be infused without producing glycosuria is 0.5 g/kg of body weight /hr. About 95% of the dextrose is retained when infused at a rate of 0.8 g/kg/hr.

Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.

A list of nutritional admixture values is appended.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. (See PRECAUTIONS).
Few systemic data have been collected on the metabolism of bupropion following concomitant administration with other drugs or, alternatively, the effect of concomitant administration of bupropion on the metabolism of other drugs.

Because bupropion is extensively metabolized, the coadministration of other drugs may affect its clinical activity. In vitro studies indicate that bupropion is primarily metabolized to hydroxybupropion by the CYP2B6 isoenzyme. Therefore, the potential exists for a drug interaction between bupropion hydrochloride tablets and drugs that are substrates or inhibitors of the CYP2B6 isoenzyme (e.g., orphenadrine, thiotepa, and cyclophosphamide). In addition, in vitro studies suggest that paroxetine, sertraline, norfluoxetine, and fluvoxamine as well as nelfinavir, ritonavir, and efavirenz inhibit the hydroxylation of bupropion. No clinical studies have been performed to evaluate this finding. The threohydrobupropion metabolite of bupropion does not appear to be produced by the cytochrome P450 isoenzymes. The effects of concomitant administration of cimetidine on the pharmacokinetics of bupropion and its active metabolites were studied in 24 healthy young male volunteers. Following oral administration of two 150 mg sustained-release tablets with and without 800 mg of cimetidine, the pharmacokinetics of bupropion and hydroxybupropion were unaffected. However, there were 16% and 32% increases in the AUC and Cmax, respectively, of the combined moieties of threohydrobupropion and erythrohydrobupropion.

While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).

Multiple oral doses of bupropion had no statistically significant effects on the single dose pharmacokinetics of lamotrigine in 12 healthy volunteers.

Animal data indicated that bupropion may be an inducer of drug-metabolizing enzymes in humans. In one study, following chronic administration of bupropion, 100 mg 3 times daily to 8 healthy male volunteers for 14 days, there was no evidence of induction of its own metabolism. Nevertheless, there may be the potential for clinically important alterations of blood levels of coadministered drugs.
This study focuses on the promising use of biospeckle technology to detect water stress in plants, a complex physiological mechanism. This involves monitoring the temporal activity of biospeckle pattern to study the occurrence of stress within the leaf. The effects of water stress in plants can involve physical and biochemical changes. Some of these changes may alter the optical scattering properties of leaves. The present study therefore proposes to test the potential of a biospeckle measurement to observe the temporal evolution in different varieties of sunflower plants under water stress. An experiment applying controlled water stress with osmotic shock using polyethylene glycol 6000 (PEG) was conducted on two sunflower varieties: one sensitive, and the other more tolerant to water stress. Temporal monitoring of biospeckle activity in these plants was performed using the average value of difference (AVD) indicator. Results indicate that AVD highlights the difference in biospeckle activity between day and night, with lower activity at night for both varieties. The addition of PEG entailed a gradual decrease in values throughout the experiment, particularly for the sensitive variety. The results obtained are consistent with the behaviour of the varieties submitted to water stress. Indeed, a few days after the introduction of PEG, a stronger decrease in AVD indicator values was observed for the sensitive variety than for the resistant variety. This study highlights the dynamics of biospeckle activity for different sunflower varieties undergoing water stress and can be considered as a promising phenotyping tool.
The present invention relates to a kind of synthetic polypeptide F and anti-bacteria and anti-virus application thereof of ring-type. Does the synthetic polypeptide F of ring-type involved in the present invention have SEQ in sequence list? ID? amino acid sequence shown in No.1 and architectural feature; Is the synthetic polypeptide F of this ring-type derived from SEQ in sequence list? ID? the LPS binding structural domain of the ALFFc of Fenneropenaeus chinensis Anti-LPS factor shown in No.2; Through the synthetic polypeptide F of the ring-type the present invention relates to is carried out to biological function Validation in vitro, confirm that its growth or propagation to gram-positive bacteria, Gram-negative bacteria or virus all has very strong inhibitory action.
Neonates in this group will receive isotonic/normal saline with 5% dextrose in 0.9% saline as their maintenance fluid therapy post-surgery. This intervention aims to maintain serum sodium levels and reduce the risk of hyponatremia and other complications.
Obesity has emerged as a worldwide epidemic. Both butyrate and glutamine counteract obesity-related metabolic disorders; however, whether and how they synergistically cooperate with each other remains a mystery. In the study, a high-fat diet (HFD, 60% calories from fat) was used to develop a model of obesity-related metabolic disorder and compared with administrated saline and sodium butyrate (SB, 300 mg/kg body weight) daily by gavage. Compared with HFD counterparts, oral administration of SB in mice exhibited significantly reduced body weight and fat mass and decreased hepatic triglyceride content. The targeted mass spectrum revealed that SB restored serum contents of glutamine, which were significantly decreased by HFD. Furthermore, SB significantly elevated the expression of glutamine synthetase (GS, encoded by GLUL) in the liver, accompanied by more enrichment of H3K27ac modifications within its promoter. In summary, the study verified the contribution of elevated glutamine to the beneficial effects of butyrate on metabolic disorders induced by a high-fat diet, providing a novel pathway for understanding how butyrate benefits metabolic homeostasis.
The efficacy of dorzolamide hydrochloride ophthalmic solution was demonstrated in clinical studies in the treatment of elevated intraocular pressure in patients with glaucoma or ocular hypertension (baseline IOP ≥ 23 mmHg). The IOP-lowering effect of dorzolamide hydrochloride ophthalmic solution was approximately 3 to 5 mmHg throughout the day and this was consistent in clinical studies of up to one year duration.

The efficacy of dorzolamide hydrochloride ophthalmic solution when dosed less frequently than three times a day (alone or in combination with other products) has not been established.

In a one year clinical study, the effect of dorzolamide hydrochloride ophthalmic solution 2% three times daily on the corneal endothelium was compared to that of betaxolol ophthalmic solution twice daily and timolol maleate ophthalmic solution 0.5% twice daily. There were no statistically significant differences between groups in corneal endothelial cell counts or in corneal thickness measurements. There was a mean loss of approximately 4% in the endothelial cell counts for each group over the one year period.
The augmented intervention will consist of just-in-time nurse, patient and physician information and feedback during the post-acute period, plus transition to an ongoing Home-Based HTN Support Program within approximately 30 days after the patient's admission to home health care. The augmented intervention adds an HTN Nurse Specialist (advanced practice nurse) and a lay community health worker, who will be responsible for assuring a patient's smooth transition to the Home-Based HTN Support Program and for delivering the main components of that intervention, backed up by the project physician.
BACKGROUND: Papillary tumors of pineal region (PTPR) comprise a very rare subset of pineal region tumors that have been recently described. Literature on the management and outcome of PTPR is scarce owing to the rarity of these tumors. To address this lacuna, we analyzed our experience in management of PTPR.
METHODS: We retrospectively analyzed the outcome of 11 patients with histopathologically proven PTPR who underwent surgical excision at our center.
RESULTS: Mean patient age was 33.3 years (range, 12-45 years), and male-to-female ratio was 1.75:1. Headache was the most common presentation followed by visual disturbances, altered sensorium, Perinaud syndrome, and seizures. Cerebrospinal fluid diversion was required in 6 patients. Krause approach was the most common approach used for tumor excision (9/11 cases). There was no perioperative mortality. Two patients were lost to follow-up. In the remaining 9 patients, the average follow-up period was 45 months (range, 12-79 months). On first postoperative magnetic resonance imaging, 8 patients showed no evidence of residual tumor (gross total resection), while 1 patient had small residual tumor (near-total resection) that remained stable during follow-up. Four patients underwent adjuvant chemoradiotherapy. None of the patients developed recurrence during follow-up.
CONCLUSIONS: PTPR are a rare subgroup of pineal region tumors with distinct cells of origin but presentation similar to other pineal region tumors. Surgical resection constitutes the mainstay of management, and the extent of resection appears to be the most important determinant of prognosis. The role of adjuvant therapy still needs to be determined.
The invention discloses an ansha full-carbon ring polyketone antibiotic and application thereof in preparing antibacterial drugs or antitumor drugs. Marine verrucaria (Verrucosispora sp.) SCSIO 07399 was deposited at 22 months 10 and 2018 at the guangdong province collection of microbial cultures (GDMCC) address: the preservation numbers of No. 59 building 5 of the Zhou Mieli 100 college in Guangzhou city, Guangdong province microbial research institute are as follows: GDMCC No. 60466. The fermentation culture of the marine verrucaria (Verrucosispora sp.) SCSIO 07399 can prepare a new compound kendomycin B-D shown in formulas (I) to (III), and the three compounds have obvious antibacterial and antitumor activities and wide application prospects.
Peyronie's Disease treatment with Xiaflex® and Aveed®. All 20 subjects will be treated with Xiaflex® and Aveed®. The data collected from this pilot project will be analyzed and compared to historical data regarding treatment for PD with Xiaflex® alone.
Lysophosphatidic acid (LPA)-mediated activation of LPA receptor 1 (LPAR1) contributes to the pathophysiology of fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc). These diseases are associated with high morbidity and mortality despite current treatment options. The LPA-producing enzyme autotaxin (ATX) and LPAR1 activation contribute to inflammation and mechanisms underlying fibrosis in preclinical fibrotic models. Additionally, elevated levels of LPA have been detected in bronchoalveolar lavage fluid from patients with IPF and in serum from patients with SSc. Thus, ATX and LPAR1 have gained considerable interest as pharmaceutical targets to combat fibrotic disease and inhibitors of these targets have been investigated in clinical trials for IPF and SSc. The goals of this review are to summarise the current literature on ATX and LPAR1 signalling in pulmonary fibrosis and to help differentiate the novel inhibitors in development. The mechanisms of action of ATX and LPAR1 inhibitors are described and preclinical studies and clinical trials of these agents are outlined. Because of their contribution to numerous physiologic events underlying fibrotic disease, ATX and LPAR1 inhibition presents a promising therapeutic strategy for IPF, SSc and other fibrotic diseases that may fulfil unmet needs of the current standard of care.